Anti-IL-23p19 therapy inhibits the adoptive transfer of syngeneic graft-versus-host disease.

Abstract

Syngeneic graft-versus-host disease (SGVHD), a chronic inflammatory disease, develops following irradiation, syngeneic bone marrow transplantation (BMT) and treatment with the immunosuppressive agent cyclosporine A (CsA). We have shown that TH1 and TH17 cytokine responses are increased during the development of SGVHD. The current study was designed to further investigate the involvement of TH17 immunity in SGVHD-associated colitis. IL-23 is a TH17 cytokine responsible for maintaining the effector functions of TH17 cells. The administration of anti-mouse IL-23p19 was shown to significantly reduce the clinical symptoms of primary and secondary SGVHD-associated colitis resulting in a significant reduction in both TH1 and TH17 associated cytokine expression. These results demonstrate that the TH17-associated cytokine, IL-23, may prove to be a beneficial therapeutic target in the treatment of chronic colon inflammation.

• Authors: J Anthony Brandon, C Darrell Jennings, Alan M Kaplan, J Scott Bryson
• Journal: Cytokine (Cytokine) Vol. 61 Issue 3 Pg. 732-5 (Mar 2013) ISSN: 1096-0023 [Electronic] England
• PMID: 23402791 (Publication Type: Journal Article)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Cytokines
• Inflammation Mediators
• Interleukin-23 Subunit p19

Topics

• Adoptive Transfer
• Animals
• Cytokines (biosynthesis)
• Female
• Graft vs Host Disease (immunology, therapy)
• Inflammation Mediators (metabolism)
• Interleukin-23 Subunit p19 (antagonists & inhibitors, metabolism)
• Mice
• Transplantation, Isogeneic